Toll-like Receptor 7 and TLR9 Dictate Autoantibody Specificity and Have Opposing Inflammatory and Regulatory Roles in a Murine Model of Lupus

Immunity

Volumn 25, Issue 3, 2006, Pages 417-428

  Christensen, Sean R ^a   Shupe, Jonathan ^a   Nickerson, Kevin ^a   Kashgarian, Michael ^a   Flavell, Richard A ^a   Shlomchik, Mark J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CELLIMMUNO; HUMDISEASE; MOLIMMUNO

Indexed keywords

ALPHA INTERFERON; ANTIGEN; AUTOANTIBODY; DNA; DNA ANTIBODY; IMMUNOGLOBULIN G; RNA; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CELL ACTIVATION; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MODEL; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE ACTIVATION; MALE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODY SPECIFICITY; AUTOANTIBODIES; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; MICE, KNOCKOUT; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9;

EID: 33748472865     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immuni.2006.07.013     Document Type: Article

References (50)

1. Akira S. Toll-like receptor signaling. J. Biol. Chem. 278 (2003) 38105-38108
2. Alba P., Bento L., Cuadrado M.J., Karim Y., Tungekar M.F., Abbs I., Khamashta M.A., D'Cruz D., and Hughes G.R. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann. Rheum. Dis. 62 (2003) 556-560
3. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., Shark K.B., Grande W.J., Hughes K.M., Kapur V., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100 (2003) 2610-2615
4. Barrat F.J., Meeker T., Gregorio J., Chan J.H., Uematsu S., Akira S., Chang B., Duramad O., and Coffman R.L. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202 (2005) 1131-1139
5. Bekeredjian-Ding I.B., Wagner M., Hornung V., Giese T., Schnurr M., Endres S., and Hartmann G. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174 (2005) 4043-4050
6. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., and Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197 (2003) 711-723
7. Boule M.W., Broughton C., Mackay F., Akira S., Marshak-Rothstein A., and Rifkin I.R. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199 (2004) 1631-1640
8. Christensen S.R., Kashgarian M., Alexopoulou L., Flavell R.A., Akira S., and Shlomchik M.J. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202 (2005) 321-331
9. Cohen P.L., and Eisenberg R.A. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9 (1991) 243-269
10. Cohen P.L., Caricchio R., Abraham V., Camenisch T.D., Jennette J.C., Roubey R.A., Earp H.S., Matsushima G., and Reap E.A. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J. Exp. Med. 196 (2002) 135-140
11. Dong L., Ito S., Ishii K.J., and Klinman D.M. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum. 52 (2005) 651-658
12. Edwards A.D., Diebold S.S., Slack E.M., Tomizawa H., Hemmi H., Kaisho T., Akira S., and Reis e Sousa C. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol. 33 (2003) 827-833
13. Egner W. The use of laboratory tests in the diagnosis of SLE. J. Clin. Pathol. 53 (2000) 424-432
14. Ehlers M., Fukuyama H., McGaha T.L., Aderem A., and Ravetch J.V. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. 203 (2006) 553-561
15. Emlen W., and O'Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum. 40 (1997) 1612-1618
16. Honda K., Ohba Y., Yanai H., Negishi H., Mizutani T., Takaoka A., Taya C., and Taniguchi T. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434 (2005) 1035-1040
17. Isenberg D.A., Dudeney C., Williams W., Addison I., Charles S., Clarke J., and Todd-Pokropek A. Measurement of anti-DNA antibodies: a reappraisal using five different methods. Ann. Rheum. Dis. 46 (1987) 448-456
18. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5 (2004) 987-995
19. Kirou K.A., Lee C., George S., Louca K., Peterson M.G., and Crow M.K. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52 (2005) 1491-1503
20. Kobayashi K., Hernandez L.D., Galan J.E., Janeway Jr. C.A., Medzhitov R., and Flavell R.A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110 (2002) 191-202
21. Krug A., French A.R., Barchet W., Fischer J.A., Dzionek A., Pingel J.T., Orihuela M.M., Akira S., Yokoyama W.M., and Colonna M. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21 (2004) 107-119
22. Lau C.M., Broughton C., Tabor A.S., Akira S., Flavell R.A., Mamula M.J., Christensen S.R., Shlomchik M.J., Viglianti G.A., Rifkin I.R., and Marshak-Rothstein A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202 (2005) 1171-1177
23. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., and Tough D.F. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14 (2001) 461-470
24. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., and Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416 (2002) 603-607
25. Liew F.Y., Xu D., Brint E.K., and O'Neill L.A. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5 (2005) 446-458
26. Losman M.J., Fasy T.M., Novick K.E., and Monestier M. Monoclonal autoantibodies to subnucleosomes from a MRL/Mp(-)+/+ mouse. Oligoclonality of the antibody response and recognition of a determinant composed of histones H2A, H2B, and DNA. J. Immunol. 148 (1992) 1561-1569
27. Losman M.J., Fasy T.M., Novick K.E., and Monestier M. Relationships among antinuclear antibodies from autoimmune MRL mice reacting with histone H2A-H2B dimers and DNA. Int. Immunol. 5 (1993) 513-523
28. Lovgren T., Eloranta M.L., Bave U., Alm G.V., and Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50 (2004) 1861-1872
29. Means T.K., Latz E., Hayashi F., Murali M.R., Golenbock D.T., and Luster A.D. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115 (2005) 407-417
30. Migliorini P., Baldini C., Rocchi V., and Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity 38 (2005) 47-54
31. Moseman E.A., Liang X., Dawson A.J., Panoskaltsis-Mortari A., Krieg A.M., Liu Y.J., Blazar B.R., and Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J. Immunol. 173 (2004) 4433-4442
32. Muro Y. Antinuclear antibodies. Autoimmunity 38 (2005) 3-9
33. Negishi H., Ohba Y., Yanai H., Takaoka A., Honma K., Yui K., Matsuyama T., Taniguchi T., and Honda K. Negative regulation of Toll-like-receptor signaling by IRF-4. Proc. Natl. Acad. Sci. USA 102 (2005) 15989-15994
34. Nimmerjahn F., and Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310 (2005) 1510-1512
35. Patole P.S., Zecher D., Pawar R.D., Grone H.J., Schlondorff D., and Anders H.J. G-rich DNA suppresses systemic lupus. J. Am. Soc. Nephrol. 16 (2005) 3273-3280
36. Pisitkun P., Deane J.A., Difilippantonio M.J., Tarasenko T., Satterthwaite A.B., and Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312 (2006) 1669-1672
37. Plotz P.H. The autoantibody repertoire: searching for order. Nat. Rev. Immunol. 3 (2003) 73-78
38. Santiago-Raber M.L., Baccala R., Haraldsson K.M., Choubey D., Stewart T.A., Kono D.H., and Theofilopoulos A.N. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197 (2003) 777-788
39. Sato S., Takeuchi O., Fujita T., Tomizawa H., Takeda K., and Akira S. A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and -independent pathways. Int. Immunol. 14 (2002) 783-791
40. Savarese E., Chae O.W., Trowitzsch S., Weber G., Kastner B., Akira S., Wagner H., Schmid R.M., Bauer S., and Krug A. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107 (2006) 3229-3234
41. Subramanian S., Tus K., Li Q.Z., Wang A., Tian X.H., Zhou J., Liang C., Bartov G., McDaniel L.D., Zhou X.J., et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl. Acad. Sci. USA 103 (2006) 9970-9975
42. Takahashi S., Nose M., Sasaki J., Yamamoto T., and Kyogoku M. IgG3 production in MRL/lpr mice is responsible for development of lupus nephritis. J. Immunol. 147 (1991) 515-519
43. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., Schaller J.G., Talal N., and Winchester R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25 (1982) 1271-1277
44. Theofilopoulos A.N., Baccala R., Beutler B., and Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev. Immunol. 23 (2005) 307-336
45. Uematsu S., Sato S., Yamamoto M., Hirotani T., Kato H., Takeshita F., Matsuda M., Coban C., Ishii K.J., Kawai T., et al. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J. Exp. Med. 201 (2005) 915-923
46. Viglianti G.A., Lau C.M., Hanley T.M., Miko B.A., Shlomchik M.J., and Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity 19 (2003) 837-847
47. Vinuesa C.G., and Goodnow C.C. Immunology: DNA drives autoimmunity. Nature 416 (2002) 595-598
48. Vollmer J., Tluk S., Schmitz C., Hamm S., Jurk M., Forsbach A., Akira S., Kelly K.M., Reeves W.H., Bauer S., and Krieg A.M. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202 (2005) 1575-1585
49. Werwitzke S., Trick D., Kamino K., Matthias T., Kniesch K., Schlegelberger B., Schmidt R.E., and Witte T. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse. Arthritis Rheum. 52 (2005) 3629-3638
50. Wu X., and Peng S.L. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum. 54 (2006) 336-342